20 September 2021
The Ministry of Health of the Russian Federation proposed to approve indicators of the risk of violation of mandatory requirements in the implementation of federal state control (supervision) of biomedical cell products circulation. The draft of the corresponding order is published at regulation.gov.ru.
The authors of the document believe that a tenfold or higher increase in the number of reports in a calendar year on side effects and adverse reactions during the use of a biomedical cell product should be used as an indicator. In the statistics, it is necessary to take into account both messages from the owners of registration certificates and from other persons authorized to collect such information. The data will be compared with the same indicators of the previous year.
The risk indicator is a value of parameter of the controlled object beyond which the negative consequences of activities significantly increase and a threat of harm to the life and health of citizens may emerge.
Print14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024